Novo Nordisk Collaborates With Life Edit Therapeutics
Novo Nordisk And Life Edit Therapeutics Announced A Research And Development Collaboration To Discover And Develop Gene Editing Therapies Against A Select Set Of Therapeutic Targets.Under The Agreement, Life Edit Will Receive An Upfront Cash Payment And Is Eligible To Receive Potential Development, Regulatory, And Commercial Milestones Of 335 Million Us Dollars For Each Of The First Two Development Programmes Under The Collaboration And Up To 250 Million Dollars For Each Of The Following Five Development Programmes Under The Collaboration. The Collaboration Between The Two Companies Allows For Development Of Up To Seven Programmes. Moreover, This Opportunity Will Co-Create Novel Treatments For Multiple Genetic Diseases Based On Life Edit
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!